Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Rapidly Identifies Low Risk of Cardiac Event

By LabMedica International staff writers
Posted on 21 Oct 2015
A test that measures blood for the cardiac troponin protein, which is released by damaged heart cells, may help doctors rule out heart attack faster in patients with similar symptoms.

Suspected acute coronary syndrome is the most common reason for emergency admission to hospital and is a large burden on health-care resources and strategies to identify low-risk patients suitable for immediate discharge would have major benefits.

Medical scientists at the University of Edinburgh (UK) consecutively enrolled 6,304 patients with suspected acute coronary syndrome presenting to four secondary and tertiary care hospitals in Scotland in a prospective cohort study. They assessed the threshold of cardiac troponin in two independent validation cohorts. The first validation cohort included 1,126 consecutively enrolled patients with suspected acute coronary syndrome and the second included 308 consecutively enrolled patients at a different medical center.

As standard of care, a sensitive cardiac troponin I assay (ARCHITECTSTAT troponin I assay; Abbott Laboratories, Abbott Park, IL, USA) was used for clinical decision making and the result declared to the patients' clinicians. The assay has a limit of detection of 1.2 ng/L, and an upper reference limit (99th centile) of 34 ng/L in men and 16 ng/L in women. In derivation and validation cohorts, they evaluated the negative predictive value of a range of troponin concentrations for the primary outcome of index myocardial infarction, or subsequent myocardial infarction or cardiac death at 30 days.

The investigators found that 782 of 4,870 (16%) patients in the derivation cohort had index myocardial infarction, with a further 32 (1%) re-presenting with myocardial infarction and 75 (2%) cardiac deaths at 30 days. In patients without myocardial infarction at presentation, troponin concentrations were less than 5 ng/L in 2,311 of 3,799 (61%) patients, with a negative predictive value of 99.6% for the primary outcome. In two independent validation cohorts, troponin concentrations were less than 5 ng/L in 594 of 1,061 (56%) patients, with an overall negative predictive value of 99.4%. At one year, these patients had a lower risk of myocardial infarction and cardiac death than did those with a troponin concentration of 5 ng/L or more.

The authors concluded that low plasma troponin concentrations identified two-thirds of patients at very low risk of cardiac events who could be discharged from hospital. Implementation of this approach could substantially reduce hospital admissions and have major benefits for both patients and health-care providers. The study was published on October 7, 2015, in the journal the Lancet.

Related Links:

University of Edinburgh 
Abbott Laboratories 



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Multi-Function Pipetting Platform
apricot PP5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.